Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S reported a successful 2023 with significant innovation and growth, reaching a record 40 million patients globally. The company’s Annual General Meeting saw the approval of the Annual Report, a final dividend of DKK 6.40 per share, and the re-election of board members. Novo Nordisk, a leader in healthcare with a focus on defeating chronic diseases, continues to expand its market presence and invest in production capacity to serve an increasing number of patients worldwide.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
